tldrdaily.news logo

FDA Concludes: No Evidence of Weight-Loss Drugs Causing Suicidal Thoughts

1 min read
Source: FDA.gov
FDA Concludes: No Evidence of Weight-Loss Drugs Causing Suicidal Thoughts
Photo: FDA.gov
TL;DR Summary

The FDA has conducted a preliminary evaluation of reports of suicidal thoughts or actions in patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity, finding no evidence of a causal link. While additional evaluations are ongoing, including a meta-analysis of clinical trials and an analysis of postmarketing data, patients are advised not to stop taking GLP-1 RAs without consulting a healthcare professional. Healthcare professionals should monitor and advise patients to report any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. The FDA encourages reporting of side effects involving GLP-1 RAs or other medicines to the FDA MedWatch program.

Topics:business#diabetes#fda#glp-1-ras#health-medicine#obesity#suicidal-thoughts
Share this article
  1. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity  FDA.gov
  2. Weight-Loss Drugs Don't Cause Suicidal Thoughts, FDA Says  The Wall Street Journal
  3. AP Trending SummaryBrief at 2:46 p.m. EST | National | heraldpalladium.com  Herald Palladium
  4. FDA reports no link between weight-loss drugs and suicidal thoughts  The Washington Post
  5. FDA finds no evidence that Ozempic, similar drugs cause suicidal thoughts in preliminary evaluation  CNN

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

4 min

vs 5 min read

Condensed

88%

902 → 108 words

Want the full story? Read the original article

Read on FDA.gov